Table 2 Risk ratio for the association between Bcl-2 expression and response to chemotherapy

All studies

OR

23

[12–34]

1.16(1.02–1.32)

0.026*

11.6

0.502

CR

12

[12–15, 20, 22, 24, 25, 27, 28, 30],[31]

1.67(1.24–2.24)

0.001*

15.8

0.289

Pathological CR

10

[12–15, 20, 22, 24, 25, 27, 28]

1.92(1.38–2.69)

<0.001*

10.9

0.342

Response to NCT

OR

19

[12–18, 20–22, 24–26, 28, 30–34]

1.19(1.04–1.37)

0.014*

17.7

0.234

CR

12

[12–15, 20, 22, 24, 25, 27, 28, 30],[31]

1.67(1.24–2.24)

0.001*

15.8

0.289

Pathological CR

10

[12–15, 20, 22, 24, 25, 27, 28]

1.92(1.38–2.69)

<0.001*

10.9

0.342

Response to anthracycline-based

OR

15

[12, 14–22, 24–29]

1.20(1.01–1.43)

0.034*

15.5

0.280

Pathological CR

9

[12, 14, 15, 20, 22, 24, 25, 27],[28]

1.76(1.24-2.51)

0.002*

0.0

0.452

Response to docetaxel-based

OR

8

[12–15, 17, 19, 23, 28]

1.37(0.88–2.14)

0.160^#

46.3

0.071

Pathological CR

4

[12–14, 28]

2.11(1.14–3.88)

0.017*

0.0

0.525